ARTICLE | Company News
GlaxoSmithKline sales and marketing update
September 1, 2014 7:00 AM UTC
GlaxoSmithKline launched Tanzeum albiglutide in the U.S. to treat Type II diabetes as monotherapy or as add-on therapy. The wholesale acquisition cost of 4 injections of 30 or 50 mg once-weekly Tanze...